| Literature DB >> 23239297 |
Dae Ro Lim1, Byung Soh Min, Min Sung Kim, Sami Alasari, Gangmi Kim, Hyuk Hur, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim.
Abstract
BACKGROUND: Robotically assisted colon resection is a new type of surgery for colon cancer. However, the evidence is inadequate for the general adaptation of robotic colon surgery. This study aimed to show the oncologic and perioperative clinical results of robotically assisted anterior resection (R-AR) compared with those of laparoscopically assisted anterior resection (L-AR) for sigmoid colon cancer.Entities:
Mesh:
Year: 2012 PMID: 23239297 PMCID: PMC3599163 DOI: 10.1007/s00464-012-2619-3
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Patient characteristics (n = 180)
| Laparoscopic anterior resection ( | Robotic anterior resection ( |
| |
|---|---|---|---|
| Mean age: years (range) | 59.7 ± 11.5 (29–90) | 59.6 ± 8.4 (41–77) | 0.969 |
| Sex: | 0.439 | ||
| Male | 87 (59.6) | 23 (67.6) | |
| Female | 59 (40.4) | 11 (32.4) | |
| Mean weight: kg (range) | 63.3 ± 11.9 (37–113) | 66.7 ± 10.0 (48–93) | 0.123 |
| Mean height: cm (range) | 163 ± 8 (135–184) | 164 ± 9 (146–185) | 0.481 |
| Mean BMI: kg/m2 (range) | 23.8 ± 3.8 (16.0–39.1) | 24.8 ± 2.1 (20.8–29.4) | 0.135 |
| ASA score: | 0.134 | ||
| 1 | 107 (73.3) | 19 (55.9) | |
| 2 | 33 (22.6) | 13 (38.2) | |
| 3 | 6 (4.1) | 2 (1.4) | 0.931 |
| Mean tumor location from anal verge: cm (range) | 25.9 ± 7.1 (13–50) | 22.2 ± 7.2 (10–40) | |
| Previous operation history: | 25 (17.1) | 4 (11.7) | 0.606 |
BMI body mass index, ASA American Society of Anesthesiologists
Perioperative clinical outcomes and postoperative complications
| Laparoscopic anterior resection ( | Robotic anterior resection ( |
| |
|---|---|---|---|
| Perioperative clinical outcomes | |||
| Mean total operation time: min (range) | 217.6 ± 70.7 (82–400) | 252.5 ± 94.9 (117–460) | 0.016 |
| Mean intraoperative bleeding: ml (range) | 78.2 ± 12.3 (0–600) | 60.3 ± 27.0 (0–800) | 0.772 |
| Mean time to 1st gas passing: days (range) | 2.52 ± 0.8 (1–5) | 2.21 ± 0.9 (1–5) | 0.040 |
| Mean time to 1st stool passing: days (range) | 4.42 ± 0.9 (2–7) | 3.85 ± 0.2 (2–7) | 0.003 |
| Mean time to soft diet:days (range) | 5.2 ± 1.3 (3–16) | 4.5 ± 1.2 (2–7) | 0.009 |
| Mean hospital stay: (range) | 6.2 ± 1.3 (4–17) | 5.5 ± 1.6 (3–8) | 0.005 |
| Conversion | |||
| Postoperative complications: | |||
| Mild complications | |||
| Chyloperitoneum | 4 (2.7) | 0 (0) | |
| Ileus | 1 (0.7) | 2 (5.9) | |
| Wound infection | 2 (1.4) | 0 (0) | |
| Voiding difficulty | 5 (3.4) | 0 (0) | |
| Moderate complications | |||
| Pneumonia | 0 (0) | 0 (0) | |
| Postoperative bleeding | 1 (0.7) | 0 (0) | |
| Severe complications | |||
| Intraabdominal abscess | 0 (0) | 0 (0) | |
| Anastomotic leakage | 2 (1.4) | 0 (0) | |
| Deaths (30-day mortality) | 0 (0) | 0 (0) | |
| Total no. of complications | 15 (10.3) | 2 (5.9) | 0.281 |
| Total no. of patients with complications | 15 (10.3) | 2 (5.9) | 0.281 |
| Readmission due to complications | 1 (0.7) | 1 (2.9) | 0.258 |
Postoperative pathologic outcomes
| Laparoscopic anterior resection ( | Robotic anterior resection ( |
| |
|---|---|---|---|
| TNM stage: | 0.185 | ||
| 1 | 52 (35.6) | 14 (41.2) | |
| 2 | 36 (24.7) | 12 (35.3) | |
| 3 | 58 (39.7) | 8 (23.5) | |
| T stage: | 0.954 | ||
| 1 | 38 (26.0) | 9 (26.5) | |
| 2 | 24 (16.4) | 5 (14.7) | |
| 3 | 78 (53.4) | 19 (55.9) | |
| 4 | 6 (4.1) | 1 (2.9) | |
| N stage: | 0.233 | ||
| 0 | 89 (61.0) | 26 (76.5) | |
| 1 | 48 (32.9) | 7 (20.6) | |
| 2 | 9 (6.1) | 1 (2.9) | |
| Mean harvested lymph nodes: | |||
| All stage | 16.5 ± 11.3 (2–56) | 12.0 ± 7.9 (1–31) | 0.031 |
| Stage 1 | 13.1 ± 11.9 (2–56) | 7.7 ± 5.8 (1–21) | 0.080 |
| Stage 2 | 18.2 ± 8.8 (5–46) | 15.5 ± 8.4 (3–26) | 0.404 |
| Stage 3 | 18.5 ± 11.5 (4–52) | 14.4 ± 8.1 (5–46) | 0.387 |
| Mean PRM: cm (range) | 8.2 ± 2.9 (3–19) | 10.7 ± 3.4 (3.5–35) | 0.026 |
| Mean DRM: cm (range) | 4.9 ± 2.8 (1–25) | 5.4 ± 3.4 (1–20) | 0.452 |
TNM tumor node metastasis, PRM proximal margin, DRM distal margin
Fig. 1The 3-year overall (A) and 3-year disease-free (B) survival rates
Fig. 2The 3-year overall and disease-free survival rates according to stage. A 3-year overall survival for stage 2. B 3-year disease-free survival for stage 2. C 3-year overall survival for stage 3 D 3-year disease-free survival for stage 3